Cagrilintide vs Tirzepatide

Cagrilintide vs Tirzepatide is an investigational amylin-only drug versus an FDA-approved dual GIP/GLP-1 medicine. Separate Phase 3 trials found about 11–12% average weight loss with cagrilintide alone at 68 weeks and 20.9% with tirzepatide 15 mg at 72 weeks, but no trial has compared those monotherapies directly.

What is the core difference?

Cagrilintide works through amylin, while tirzepatide works through two incretin pathways, GIP and GLP-1. Cagrilintide copies a pancreatic hormone released alongside insulin that signals fullness, slows stomach emptying, and tempers post-meal glucagon. Tirzepatide sends two gut-hormone signals that affect appetite and glucose control. Both are weekly peptides; the receptor map is not the same.

That distinction matters because the shorthand search amylin analog vs zepbound can make the comparison sound like two approved products on the same pharmacy shelf. Zepbound is an approved brand of tirzepatide. Cagrilintide has no standalone FDA approval or branded prescription product. The amylin program has produced serious human evidence, but development status is not a minor footnote.

What do the weight-loss trials actually show?

Cagrilintide alone produced about 11.5% mean weight loss at 68 weeks in REDEFINE 1 under the treatment-regimen analysis; the estimate was 11.8% under the analysis assuming participants stayed on treatment. Tirzepatide 15 mg produced 20.9% at 72 weeks in SURMOUNT-1 under its treatment-regimen analysis. Those are substantial human RCT results, not animal extrapolations.

The REDEFINE 1 publication enrolled adults with overweight or obesity without diabetes and included cagrilintide 2.4 mg, semaglutide 2.4 mg, their combination, and placebo. A published REDEFINE 1 analysis reports the 11.8% cagrilintide estimate at week 68. Cagrilintide alone weight loss is therefore real Phase 3 evidence, not a number borrowed from CagriSema.

SURMOUNT-1 randomized 2,539 adults without diabetes to placebo or tirzepatide 5, 10, or 15 mg for 72 weeks. Mean changes were 15.0%, 19.5%, and 20.9% across those doses, versus 3.1% with placebo.

No trial has directly tested tirzepatide vs cagrilintide as monotherapies. Different participants, dose-escalation schedules, dropout patterns, and statistical analyses mean the raw percentages are not lane times from the same race. Tirzepatide has the larger published monotherapy average; that is a cross-trial observation, not proof from a randomized comparison.

Is amylin better than GLP-1?

The honest answer to is amylin better than glp-1 is that the question is too broad for the evidence. Cagrilintide shows that amylin can drive clinically meaningful weight loss on its own. Tirzepatide shows that dual GIP/GLP-1 agonism can drive a larger average in a separate trial. Neither result establishes that one hormone family is universally superior.

Amylin becomes more interesting as a complementary signal. CagriSema combines cagrilintide with semaglutide, deliberately pairing amylin with GLP-1 rather than asking one pathway to do every job. That combination has its own evidence and should not be relabeled as “cagrilintide” when comparing results. Ingredient arithmetic is not optional here.

For a plain-English map of the pathway, see what an amylin analogue is. The useful conclusion is narrower: amylin is a validated human weight-loss target, but tirzepatide currently has the stronger monotherapy efficacy and clinical-use case.

Which compound fits which goal?

Tirzepatide fits a goal of using an approved medicine now or prioritizing the largest published Phase 3 monotherapy average. The current Zepbound label covers chronic weight management and obesity-related obstructive sleep apnea, with weekly dosing escalated from 2.5 mg to maintenance doses of 5, 10, or 15 mg.

Cagrilintide fits a research goal centered specifically on amylin monotherapy. That is a mechanism pick, not a buying recommendation and not an approved substitute for Zepbound. The by-goal table reflects the asymmetry: one compound is a prescription treatment with several mature Phase 3 programs; the other is a late-stage investigational drug whose most visible development route has been the CagriSema combination.

Neither choice escapes tolerability trade-offs. Gastrointestinal effects dominate both trial programs. Tirzepatide also carries FDA label warnings for severe gastrointestinal reactions, pancreatitis, gallbladder disease, and thyroid C-cell tumors observed in rats; human relevance of the tumor finding is unknown.

What does the 2026 approval status change?

Cagrilintide is not separately FDA-approved as of July 2026, and CagriSema is still investigational rather than a route for routine patient access. Novo Nordisk filed CagriSema for US approval in December 2025, with a decision expected in late 2026. Tirzepatide is already available by prescription as Zepbound and Mounjaro.

FDA’s March 2026 warning letter on cagrilintide sales called the marketed products unapproved new drugs even when sites used “research purposes only” language. A research vial is not a back-door approved medicine. Cagrilintide’s human RCT badge describes evidence quality, not legal availability, manufacturing quality, or FDA review.

Tirzepatide’s approval does not make every version equivalent. FDA declared the tirzepatide shortage resolved, narrowing routine shortage-based compounding, while the approved products remain the versions evaluated for identity, strength, quality, and labeling. That is why cagrilintide vs tirzepatide cannot be reduced to one percentage: evidence tier, approval status, and product quality answer three different questions.